Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: my thought

I don't agree that the "big" companies are looking to take over TPL's 50%. I would suggest that you read the following provided by BaNosser

http://photos.imageevent.com/banos/tplbk/Statement%20of%20Regarding%20Status%20Of%20Objections%20To%20Disclosure%20Statement%20For%20Official%20Committee%20Of%20Unsecured%20Creditorsqu%20Plan%20Of%20Reorganization%201-22-14.pdf

To summarize:

The committee is amending the Disclosure Statement to address the issues raised by Fujitsu and the Joinder Parties (separate filing by Apple as a Joinder)

Licensees concerned that TPL's rights to commercialize might be effected and jeopardize the validity of their licenses. They requested clarifying language that the commercialization agreements that form the basis for TPL's right to commercialize the portfolios would not be rejected. The committee agreed to provide language that the commercialization contracts would be assumed or ride through the BK

Licensees are also concerned about post confirmation rejection of their licenses resulting in damages. The Committee never intended to reject those licenses and agreed to language suggested by Toshiba.

These and other concerns will be addressed in the Amended Disclosure Statements which I believe is due by 2/14/14.

Share
New Message
Please login to post a reply